Validation and Application of an HPLC-UV Method for Routine Therapeutic Drug Monitoring of Dalbavancin.

This study focuses on validation and application of an hplc-uv method for routine therapeutic drug monitoring of dalbavancin.. The research employs high-performance liquid chromatography (HPLC) techniques to address analytical challenges in the clinical field. Dalbavancin is emerging as a promising alternative in the ambulant treatment of gram-positive infections that require long-term antibiotic treatment such as osteomyelitis, prosthetic joint infections, and endocarditis. The aim of the current study was to develop and validate a simple, rapid, and cost-effective high-performance liquid chromatography-ultraviolet spectrometry (HPLC-UV) method for... Research Background and Significance Dalbavancin is a novel lipoglycopeptide antibiotic with potent activity against gram-positive pathogens, including methicillin-resistant Staphylococcus aureus (MRSA). Its pharmacokinetic profile, characterized by a prolonged half-life, makes it highly suitable for outpatient parenteral antimicrobial therapy (OPAT), particularly in infections necessitating long-term antibiotic administration such as osteomyelitis, prosthetic joint infections, and endocarditis. Therapeutic drug monitoring (TDM) is critical in optimizing dalbavancin therapy to ensure efficacy, minimize toxicity, and prevent resistance development. However, routine clinical monitoring requires robust, reliable analytical methods. The study by Chiriac et al. addresses this need by developing and validating an HPLC-UV method tailored to the clinical setting, emphasizing simplicity, rapidity, and cost-effectiveness to facilitate widespread adoption. Experimental Design and Methodology The study employed high-performance liquid chromatography coupled with ultraviolet detection (HPLC-UV) to quantify dalbavancin in human plasma